Incidence of mucositis in patients undergoing autologous hematopoietic stem cell transplantation at a single center

Authors

  • Ana Carolina Amaral Perrone PhD student on Health at Federal University of Juiz de Fora and Nurse of the Hematology and Bone Marrow Transplant Service at UFJF University Hospital
  • Clarissa Ferreira Cunha PhD in Sciences. Biomedical at the Hematology and Bone Marrow Transplant Service at UFJF University Hospital
  • Ana Paula da Silva Pinheiro Nurse at UFJF. Scientific initiation scholarship from UFJF
  • Abrahão Elias Hallack Neto Associate Professor at the Department of Clinical Medicine, Medicine Faculty, Federal University of Juiz de Fora. In charge of the Bone Marrow Transplant Service at the University Hospital of the Federal University of Juiz de Fora

DOI:

https://doi.org/10.46765/2675-374X.2020v1n1p41-45

Keywords:

Hematopoietic stem cell transplantation, Mucositis, Risk factors

Abstract

Goal: The aim of this study was to describe the incidence of oral mucositis (OM) in patients undergoing autologous hematopoietic stem cell transplantation (auto-HSCT), relating it to the main clinical factors. Methodology: Descriptive analysis based on a randomized clinical study was conducted with patients undergoing HSCT at the University Hospital of Federal University of Juiz de Fora between January 2018 and June 2019. The World Health Organi­zation oral toxicity scale was used to assess the degree of oral mucositis and adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 version. Results: Thirty-eight patients were evaluated. The incidence of OM and severe oral mucositis (SOM) was 57.9% and 21.0%, respectively. The mean duration of OM was 7.2 ± 2.6 days and the lomustine, etoposide, cytarabine and cyclophosphamide protocol (LEAC) pre­sented the longest mean time 8.1 ± 3.1 days (p-value 0.02). The number of viable CD34+ cells and the onset day of neutropenia were predictors of SOM. Conclusion: The incidence of OM in patients undergoing HSCT was lower than reported in the literature, being more severe in patients who received less CD34+ cells and in patients with early onset of neutropenia.

Downloads

Published

07/06/2020

How to Cite

Perrone, A. C. A., Cunha, C. F., Pinheiro, A. P. da S., & Hallack Neto, A. E. (2020). Incidence of mucositis in patients undergoing autologous hematopoietic stem cell transplantation at a single center. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(2), 41–45. https://doi.org/10.46765/2675-374X.2020v1n1p41-45

Issue

Vol. 1 No. 2 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Most read articles by the same author(s)